CME; non-steroidal mineralocorticoid receptor antagonists

Overview
Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (MRAs) in optimizing care for patients with chronic kidney disease and type 2 diabetes. Emerging data highlight their ability to improve cardiorenal outcomes while reducing the risk of new-onset diabetes. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.
Please check back for additional content that will be added to this program for CME credit. The maximum amount of credit available for the entire activity is 1.25 hours.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Pardeep Jhund, MD, PhD
Professor of Cardiology and Epidemiology
University of Glasgow
Glasgow, Scotland
Dr. Jhund has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alkem Metabolics, AstraZeneca, Boehringer Ingelheim, Intas Pharma, Novartis, ProAdWise Communications, Sun Pharmaceuticals
Research: AstraZeneca, Roche Diagnostics, Analog Devices Inc
Hiddo Lambers Heerspink, PhD, PharmD
Clinical Pharmacologist
University Medical Center Groningen
Groningen, Netherlands
Dr. Heerspink has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Alexion, Bayer, Boehringer Ingelheim, CSL-Behring, Dimerix, Eli Lilly, Gilead, Janssen, Novo Nordisk, Novartis, Roche, Traverere
Research: AstraZeneca, Bayer, Janssen, Novo Nordisk
John McMurray, MD, FRCP
Professor of Medical Cardiology
University of Glasgow
Glasgow, Scotland
No relevant relationship reported at this time.
Akshay S. Desai, MD, MPH, FHFSA
Director, Cardiomyopathy and Heart Failure Program
Brigham and Women’s Hospital
Boston, MA
Dr. Desai has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, GlaxoSmithKline, Merck, Medpace, Medtronic, Novartis, Parexel, Porter Health, Regeneron, Roche, River2Renal, scPharmaceuticals, Veristat, Verily, Zydus
Research: Abbott, Alnylam, AstraZeneca, Bayer, Novartis, Pfizer
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Robert Garris, PharmD, MPH, has nothing to disclose.
- Anja Gerrits has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Compare and contrast the mechanisms of action of steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRAs), highlighting their distinct effects on the mineralocorticoid receptor and downstream signaling pathways involved in the pathophysiology of cardiorenal disease
- Interpret emerging data on the potential of ns-MRAs in managing the spectrum of cardiovascular-kidney-metabolic syndrome (CKM)
- Implement best practices for initiating, titrating, and monitoring ns-MRA therapy in patients with CKM
- Develop individualized treatment plans to optimize cardiorenal outcomes in patients with CKD and T2D
Target Audience
This activity has been designed to meet the educational needs of nephrologists, cardiologists, and endocrinologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with heart failure.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until October 4, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 contact hours/ 0.125 CEUs of pharmacy contact hours.

The Universal Activity Number for this program is JA0006235-0000-24-123-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Bayer AG.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medcon International. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medcon International you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 10/04/2024
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.